Company Overview
American Healthcare Capital is proud to be the exclusive representative of a rare opportunity to acquire a highly specialized medical services and distribution platform serving a defensible, federally protected market niche. With a unique presence embedded on secured government sites across the United States and a growing international footprint, the Company has become a recognized leader in providing orthopedic bracing, medical devices, and durable medical equipment (DME) to a highly underserved yet critical population.
The business has experienced strong financial performance with double-digit EBITDA margins and is projecting meaningful revenue and profit growth in 2025. With exclusive partnerships, regulatory certifications, and government contracting opportunities already in motion, the Company is positioned for scalable, sustainable growth across military, government, and private healthcare channels.
Highlights
- Deeply Embedded, High-Barrier Market Access: Operating on secured government sites with exclusive access to federal personnel and their dependents.
- Established Clinical Network: Locations strategically positioned in key U.S. regions with planned expansions underway.
- Exclusive Product Partnerships: Long-term national partnerships with leading medical device and orthotics manufacturers.
- Government Contracting Pipeline: GSA and VA contract applications filed with expected award notifications by mid-year.
- Private Market Expansion: Recent certifications with regional and national health plans unlocking access to civilian healthcare markets.
- International Expansion: Active international deployment on secured government sites outside the U.S.
- Scalable Platform with Strong Leadership: Highly capable management team committed to staying on and rolling equity to support the next phase of growth.
Financial Snapshot
| 2022 | 2023 | 2024 | 2025-Proj. Est. | |
| Revenue | 15,141,192 | 18,028,775 | 16,439,879 | 22,000,000 |
| EBITDA | 3,466,207 | 4,883,034 | 4,055,969 | 7,000,000 |
| Margin % | 23 | 27 | 25 | 32 |
The leadership team is confident that the pipeline of new expansions, private market certifications, product launches, and government approvals will fuel double-digit revenue and EBITDA growth in the coming years.
Investment Thesis
The Company’s exclusive market positioning, proven financial performance, and clear runway for expansion make this an ideal platform for investors or strategic acquirers seeking a defensible foothold in government healthcare, with immediate opportunities to scale nationally and internationally.
The owners are seeking a capital or strategic partner to accelerate growth through geographic expansion, onsite-government contracting, and private market penetration, with leadership committed to remaining actively involved.
Asking Price
The asking price and valuation for the company shall be determined based on discussion and negotiation. The current leadership team is open to a majority equity sale, rollover equity, or an earn out. The final asking price will exclude, Cash, Accounts Receivables, Working Capital, and Real-estate holdings.
